This site is intended for healthcare professionals

Results from pivotal phase II KarMMa study of idecabtagene vicleucel to treat refractory multiple myeloma were published in NEJM. - bluebird bio + BMS

Read time: 1 mins
Last updated:26th Feb 2021
Published:26th Feb 2021
Condition: Multiple Myeloma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest